Is the fat anterior to the psoas (muscle) below the lower pole of the kidney an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The fat anterior to the psoas muscle below the lower pole of the kidney is an uncommon location for lymph node metastasis in renal cell carcinoma (kidney cancer). Renal cell carcinoma typically spreads via lymphatic drainage to the hilar, paracaval, para-aortic, and retroperitoneal lymph nodes first, as outlined in the NCCN clinical practice guidelines in oncology 1. The anterior pararenal space contains primarily fat and some blood vessels but relatively few lymph nodes compared to other retroperitoneal areas.

When kidney cancer metastasizes to lymph nodes, it more commonly affects the renal hilar nodes, paracaval nodes (for right-sided tumors), para-aortic nodes (for left-sided tumors), and interaortocaval nodes before involving more distant sites, as noted in the guidelines for kidney cancer management 1. This pattern reflects the primary lymphatic drainage pathways of the kidney. However, advanced kidney cancer can eventually spread to unusual lymphatic sites, including the anterior pararenal space, particularly in cases of aggressive disease or when more common lymphatic pathways are blocked by tumor invasion or previous treatment.

Some key points to consider in the management of kidney cancer include:

  • The importance of tumor stage, grade, and local extent in determining prognosis 1
  • The role of lymph node metastasis in the spread of kidney cancer 1
  • The need for individualized treatment approaches, taking into account unusual patient scenarios and clinical variations 1
  • The value of multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma 1

From the Research

Lymph Node Metastasis in Renal Cell Carcinoma

  • The location of lymph node metastasis in renal cell carcinoma (RCC) can vary, but there is limited information on the specific location anterior to the psoas muscle below the lower pole of the kidney.
  • A study on testicular tumors found that metastases to the psoas muscle at or below the level of the aortic bifurcation can occur 2.
  • However, there is no direct evidence to suggest that the fat anterior to the psoas muscle below the lower pole of the kidney is a common or uncommon location for lymph node metastasis in RCC.
  • Lymph node involvement in RCC is a significant prognostic factor, and accurate detection is critical for determining disease stage 3.
  • Various modalities, including MRI, CT, and FDG-PET, can be used to evaluate lymph node status in RCC, but each has its advantages and disadvantages 3.

Related Studies

  • A case study reported a solitary metastasis to the psoas muscle in a patient with RCC, highlighting the rarity of skeletal muscle metastasis in this disease 4.
  • Another study discussed the importance of lymph nodes in cancer treatment and progression, but did not specifically address the location of lymph node metastasis in RCC 5.
  • A case report of non-Hodgkin lymphoma of the kidney noted the presence of bulky psoas muscle and perinephric stranding, but this is not directly related to RCC or the specific location of lymph node metastasis in question 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Assessing lymph node status in patients with kidney cancer.

Translational andrology and urology, 2018

Research

Solitary psoas muscle metastasis after radical nephrectomy for renal cell carcinoma.

International journal of urology : official journal of the Japanese Urological Association, 2005

Related Questions

Is the fat anterior to the psoas muscle, below the lower pole of the kidney, typically considered perirenal or pararenal fat, and is it an uncommon site for lymph node metastasis in renal cell carcinoma (kidney cancer)?
Does the fat anterior to the psoas muscle (psoas major) below the lower pole of the left kidney contain lymph nodes that are part of the lymphatic chain for the kidneys and a potential location for metastatic lymph nodes from renal cell carcinoma (kidney cancer)?
Is the fat anterior to the psoas (muscle) below the lower pole of the left kidney part of the lymphatic chain for renal (kidney) cancer?
Is lymph node metastasis of kidney cancer uncommon in the perinephric fat anterior to the psoas muscle below the lower pole of the kidney?
Is fat anterior or lateral to the psoas (muscle) muscle caudal to the lower pole of the left kidney a common or uncommon site for lymph node metastasis in kidney cancer?
What is the treatment for IgG3 kappa (Immunoglobulin G3 kappa) glomerulonephritis?
What medical interventions can be done for urine with a dark brown color, resembling soda?
Which lymphomas can involve the nasopharynx?
Do positive insulin autoantibodies (IAA) affect the efficacy of insulin injections?
Is the fat anterior to the psoas (muscle) below the lower pole of the kidney an uncommon location for lymph node metastasis in kidney cancer?
Is fat anterior or lateral to the psoas (muscle) muscle caudal to the lower pole of the left kidney a common or uncommon site for lymph node metastasis in kidney cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.